Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IMMU
  • CUSIP: 45290710
  • Web: www.immunomedics.com
Capitalization:
  • Market Cap: $830.8 million
  • Outstanding Shares: 109,604,000
Average Prices:
  • 50 Day Moving Avg: $6.20
  • 200 Day Moving Avg: $4.85
  • 52 Week Range: $1.95 - $7.70
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.47
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.38 million
  • Price / Sales: 245.80
  • Book Value: ($1.20) per share
  • Price / Book: -6.32
Profitability:
  • EBIDTA: ($63,800,000.00)
  • Net Margins: -2,385.59%
  • Return on Assets: -116.00%
Debt:
  • Debt-to-Equity Ratio: -1.30%
  • Current Ratio: 1.69%
  • Quick Ratio: 1.67%
Misc:
  • Average Volume: 3.38 million shs.
  • Beta: 1.68
  • Short Ratio: 6.03
 

Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) issued its quarterly earnings data on Thursday, February, 9th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.03. The firm earned $0.38 million during the quarter, compared to the consensus estimate of $0.70 million. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

2 equities research analysts have issued 12 month price objectives for Immunomedics' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Immunomedics' share price to reach $9.00 in the next twelve months. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 28,632,680 shares, an increase of 12.4% from the April 13th total of 25,462,665 shares. Based on an average daily trading volume, of 2,159,954 shares, the days-to-cover ratio is currently 13.3 days. Currently, 28.8% of the shares of the company are short sold.

Who are some of Immunomedics' key competitors?

Who owns Immunomedics stock?

Immunomedics' stock is owned by a number of of institutional and retail investors. Top institutional investors include VENBIO SELECT ADVISOR LLC (9.90%), VENBIO SELECT ADVISOR LLC (9.90%), Vanguard Group Inc. (4.16%), State Street Corp (3.21%), Redmile Group LLC (3.08%) and FMR LLC (1.44%). Company insiders that own Immunomedics stock include Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Schwab Charles Investment Management Inc., Morgan Stanley, Wells Fargo & Company MN, ProShare Advisors LLC, TIAA CREF Investment Management LLC, Alliancebernstein L.P. and IFP Advisors Inc. Company insiders that have sold Immunomedics stock in the last year include Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, State Street Corp, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Vanguard Group Inc., FMR LLC, Perceptive Advisors LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Immunomedics stock cost?

One share of Immunomedics stock can currently be purchased for approximately $7.58.

Analyst Ratings

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (18.73% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/6/2017Jefferies Group LLCSet Price TargetBuy$9.00HighView Rating Details
5/5/2017Wells Fargo & CoUpgradeMarket Perform -> OutperformHighView Rating Details
7/29/2015Oppenheimer Holdings Inc.Reiterated RatingOutperformN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Immunomedics (NASDAQ:IMMU)
Earnings by Quarter for Immunomedics (NASDAQ:IMMU)
Earnings History by Quarter for Immunomedics (NASDAQ:IMMU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immunomedics (NASDAQ:IMMU)
2017 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ:IMMU)
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 48.83%
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.00View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.00View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Immunomedics (NASDAQ:IMMU)
Latest Headlines for Immunomedics (NASDAQ:IMMU)
Source:
DateHeadline
rttnews.com logoCompany Spotlight: Immunomedics
www.rttnews.com - May 12 at 6:36 PM
finance.yahoo.com logoEdited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT
finance.yahoo.com - May 12 at 2:04 AM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Short Interest Up 12.4% in April
www.americanbankingnews.com - May 11 at 7:34 AM
reuters.com logoBRIEF-Immunomedics Q3 loss per share $0.55
www.reuters.com - May 10 at 6:22 PM
finance.yahoo.com logoImmunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program Developments
finance.yahoo.com - May 10 at 6:22 PM
finance.yahoo.com logoImmunomedics reports 3Q loss
finance.yahoo.com - May 10 at 6:22 PM
finance.yahoo.com logoImmunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results
finance.yahoo.com - May 10 at 1:20 PM
americanbankingnews.com logoEquities Analysts Issue Forecasts for Immunomedics, Inc.'s FY2017 Earnings (IMMU)
www.americanbankingnews.com - May 10 at 9:58 AM
americanbankingnews.com logoImmunomedics (IMMU) Earns Daily Coverage Optimism Score of 0.19
www.americanbankingnews.com - May 9 at 12:50 AM
finance.yahoo.com logoImmunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : May 8, 2017
finance.yahoo.com - May 8 at 5:33 PM
bizjournals.com logoBiotech Stocks Under Scanner -- Rexahn Pharma, Peregrine Pharma, Immunomedics, and Protalix BioTherapeutics
www.bizjournals.com - May 8 at 7:18 AM
finance.yahoo.com logoImmunomedics Breaks Out, But Will It Last?
finance.yahoo.com - May 8 at 7:18 AM
finance.yahoo.com logoDid Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?
finance.yahoo.com - May 6 at 9:50 AM
americanbankingnews.com logoImmunomedics (IMMU) Receives Daily Media Sentiment Score of 0.22
www.americanbankingnews.com - May 5 at 11:22 PM
reuters.com logoBRIEF-Immunomedics announces private placement offering
www.reuters.com - May 5 at 10:54 PM
finance.yahoo.com logoImmunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value
finance.yahoo.com - May 5 at 10:54 PM
reuters.com logoBRIEF-Immunomedics announces private placement offering - Reuters
www.reuters.com - May 5 at 5:52 PM
fool.com logoWhy Immunomedics, Inc. Rocketed Today - Motley Fool
www.fool.com - May 5 at 5:52 PM
finance.yahoo.com logoWhy Immunomedics, MercadoLibre, and Pearson Jumped Today
finance.yahoo.com - May 5 at 5:52 PM
finance.yahoo.com logoImmunomedics, Seattle Genetics Scrap License Deal
finance.yahoo.com - May 5 at 5:52 PM
fool.com logoWhy Immunomedics, Inc. Rocketed Today
www.fool.com - May 5 at 2:53 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Stock Rating Upgraded by Wells Fargo & Co
www.americanbankingnews.com - May 5 at 12:34 PM
americanbankingnews.com logoImmunomedics (IMMU) Earning Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - May 3 at 12:20 AM
americanbankingnews.com logoImmunomedics (IMMU) Receiving Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 4:44 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Short Interest Down 4.5% in April
www.americanbankingnews.com - April 28 at 7:12 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Impact Immunomedics (IMMU) Stock Price
www.americanbankingnews.com - April 25 at 9:06 PM
finance.yahoo.com logoImmunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : April 25, 2017
finance.yahoo.com - April 25 at 5:22 PM
finance.yahoo.com logoImmunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : April 24, 2017
finance.yahoo.com - April 24 at 9:12 AM
fool.com logoWhy Immunomedics, Inc. Got Hammered Today - Motley Fool
www.fool.com - April 22 at 8:10 AM
americanbankingnews.com logoSomewhat Positive News Coverage Very Likely to Impact Immunomedics (IMMU) Stock Price
www.americanbankingnews.com - April 21 at 9:57 PM
americanbankingnews.com logoJefferies Group LLC Analysts Give Immunomedics, Inc. (IMMU) a $8.00 Price Target
www.americanbankingnews.com - April 21 at 4:23 PM
americanbankingnews.com logoImmunomedics (IMMU) Receives Daily Media Sentiment Score of 0.25
www.americanbankingnews.com - April 18 at 1:58 PM
americanbankingnews.com logoSomewhat Positive News Coverage Very Likely to Effect Immunomedics (IMMU) Stock Price
www.americanbankingnews.com - April 15 at 2:33 PM
americanbankingnews.com logoImmunomedics, Inc. (IMMU) Short Interest Up 12.2% in March
www.americanbankingnews.com - April 13 at 7:30 AM
finance.yahoo.com logoBattle in the Boardroom: What's Next for Immunomedics
finance.yahoo.com - April 7 at 10:25 AM
finance.yahoo.com logoImmunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression
finance.yahoo.com - April 7 at 10:25 AM
finance.yahoo.com logoBiotech Movers: Paratek Spikes 34%
finance.yahoo.com - April 7 at 10:25 AM
finance.yahoo.com logoImmunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan
finance.yahoo.com - April 7 at 10:25 AM
finance.yahoo.com logoImmunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy
finance.yahoo.com - April 7 at 10:25 AM
fool.com logoBattle in the Boardroom: What's Next for Immunomedics
www.fool.com - March 28 at 2:43 PM
americanbankingnews.com logoShort Interest in Immunomedics, Inc. (IMMU) Expands By 8.6%
www.americanbankingnews.com - March 26 at 7:26 AM
streetinsider.com logoForm 3 IMMUNOMEDICS INC For: Mar 13 Filed by: Aghazadeh Behzad - StreetInsider.com
www.streetinsider.com - March 24 at 10:56 PM
streetinsider.com logoForm 3 IMMUNOMEDICS INC For: Mar 13 Filed by: Islam Khalid - StreetInsider.com
www.streetinsider.com - March 24 at 10:56 PM
biz.yahoo.com logoIMMUNOMEDICS INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - March 16 at 4:32 PM
finance.yahoo.com logoImmunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment …
finance.yahoo.com - March 15 at 11:11 PM
us.rd.yahoo.com logoImmunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer
us.rd.yahoo.com - March 15 at 11:11 PM
thestreet.com logoBiotech Premarket Movers: Arena, Immunomedics, Aralez
www.thestreet.com - March 15 at 6:09 PM
us.rd.yahoo.com logoMarkets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS
us.rd.yahoo.com - March 10 at 7:07 PM
us.rd.yahoo.com logoJudge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN)
us.rd.yahoo.com - March 10 at 7:07 PM
biz.yahoo.com logoIMMUNOMEDICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
us.rd.yahoo.com - March 9 at 9:01 PM

Social

Chart

Immunomedics (IMMU) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff